1. Parker L, Carter SM, Williams J, Pickles K, Barratt A. Avoiding harm and supporting autonomy are under-prioritised in cancer-screening policies and practices. Eur J Cancer. 2017;85:1-5.
  2. Parker L. Including values in evidence-based policy making for breast screening: An empirically grounded tool to assist expert decision makers. Health Policy. 2017;121(7):793-9.
  3. Williams J, Carter SM, Rychetnik L. Contested Guideline Development in Australia’s Cervical Screening Program: Values Drive Different Views of the Purpose and Implementation of Organized Screening. Public Health Ethics. 2017;10(1):5-18.
  4. Degeling C, Rychetnik L, Street J, Thomas R, Carter SM. Influencing health policy through public deliberation: Lessons learned from two decades of Citizens’/community juries. Soc Sci Med. 2017;179:166-71.
  5. Carter SM. Overdiagnosis, ethics, and trolley problems: why factors other than outcomes matter—an essay by Stacy Carter. BMJ. 2017;358:j3872. (With a podcast.)
  6. Carter SM. Overdiagnosis: an important issue that demands rigour and precision: Comment on Medicalisation and overdiagnosis: what society does to medicine. Int J Health Policy Manag. 2017;6(Published online: 25 February 2017).
  7. Carter SM, Barratt A. What is overdiagnosis and why should we take it seriously in cancer screening? Public Health Research & Practice. 2017;27(3):e2731722.
  8. McGill S, Carter SM. Cancer screening: concerns, controversy and evidence. Public Health Research & Practice. 2017;27(3):e2731720.
  9. Armstrong BK BM, Frydenberg M, Gardiner RA, Haines I, Carter SM. PSA testing for men at average risk of prostate cancer. Public health research and practice. 2017;27(3):e2731721.
  10. Carter SM, Degeling C, Doust J, Barratt A. A definition and ethical evaluation of overdiagnosis. J Med Ethics. 2016;42(11):705-14.
  11. Carter SM, Doust J, Degeling C, Barratt A. A definition and ethical evaluation of overdiagnosis: response to commentaries. J Med Ethics. 2016;42:722-4.
  12. Williams JH, Carter SM. An empirical study of the ‘underscreened’ in organised cervical screening: experts focus on increasing opportunity as a way of reducing differences in screening rates. BMC Medical Ethics. 2016;17(1):1-12.
  13. Pickles K, Carter SM, Rychetnik L, McCaffery K, Entwistle V. General Practitioners’ Experiences of, and Responses to, Uncertainty in Prostate Cancer Screening: Insights from a Qualitative Study. PLoS ONE. 2016;11(4):e0153299.
  14. Pickles K, Carter SM, Rychetnik L, Entwistle VA. Doctors’ perspectives on PSA testing illuminate established differences in prostate cancer screening rates between Australia and the UK: a qualitative study. BMJ Open. 2016;6(12):e011932.
  15. Parker LM, Carter SM. The Role of Socially Embedded Concepts in Breast Cancer Screening: An Empirical Study with Australian Experts. Public Health Ethics. 2016;9(3):276–89.
  16. Jacklyn G, Glasziou P, Macaskill P, Barratt A.  Meta-analysis of breast cancer mortality benefit and over diagnosis adjusted for adherence: improving information on the effects of attending screening mammography. British Journal of Cancer. 2016; Apr 28. doi: 1038/bjc.2016.90. [Epub ahead of print]
  17. Degeling C, Carter SM, Rychetnik L. All care, but whose responsibility? Community juries reason about expert and patient responsibilities in prostate-specific antigen screening for prostate cancer. Health. 2016;20(5):465-84.
  18. Carter SM. Ethical aspects of cancer screening. Cancer Forum. 2016;40(2):105-9.
  19. Barratt A, Jacklyn GL. Challenges in Understanding and Quantifying Overdiagnosis and Overtreatment. In: Houssami N, Miglioretti D, editors. Breast Cancer Screening: An Examination of Scientific Evidence. London, UK: Elsevier; 2016.
  20. Parker L, Carter SM. Ethical and social issues in breast cancer screening. In: N. Houssami, D Miglioretti (editors),  Breast cancer screening: an examination of scientific evidence.  (pp. 347-374) London, UK: Elsevier; 2016.
  21. McCaffery KJ, Jansen J, Scherer LD, Thornton H, Hersch J, Carter SM, et al. Walking the tightrope: communicating overdiagnosis in modern healthcare. BMJ. 2016;352:i348.
  22. Parker LM, Rychetnik L, Carter SM. The role of communication in breast cancer screening: a qualitative study with Australian experts. BMC Cancer. 2015 15(Oct 19):741.
  23. Pickles K, Carter SM, Rychetnik L. Doctors’ approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study. BMJ open. 2015;5(3):e006367.
  24. Parker LM, Rychetnik L, Carter S. Framing overdiagnosis in breast screening: a qualitative study with Australian experts. BMC Cancer. 2015;15(1):1-8.
  25. Barratt A. Overdiagnosis in mammography screening: a 45 year journey from shadowy idea to acknowledged reality. BMJ. 2015;350:h867.
  26. Parker L, Rychetnik L, Carter S. Values in breast cancer screening: an empirical study with Australian experts. BMJ open. 2015;5(5):e006333.
  27. Degeling C, Rychetnik L, Pickles K, Thomas R, Doust JA, Gardiner RA, et al. “What should happen before asymptomatic men decide whether or not to have a PSA test?” A report on three community juries. Med J Aust. 2015;203(8):335.
  28. Degeling C, Carter SM, Rychetnik L. Which public and why deliberate? – A scoping review of public deliberation in public health and health policy research. Soc Sci Med. 2015;131:114-21.
  29. Carter SM, Williams J, Parker L, Pickles K, Jacklyn G, Rychetnik L, et al. Screening for Cervical, Prostate, and Breast Cancer: Interpreting the evidence. Am J Prev Med. 2015;49(2):274–85.
  30. Carter SM, Rogers W, Heath I, Degeling C, Doust J, Barratt A. The challenge of overdiagnosis begins with its definition. BMJ. 2015;350:doi 10.1136/bmj.h869. (With a podcast.)
  31. Williams JH, Carter SM, Rychetnik L. ‘Organised’ cervical screening 45 years on: How consistent are organised screening practices? Eur J Cancer. 2014;50(17):3029-38.
  32. Williams JH, Carter SM, Rychetnik L. Information provision in cervical screening in Australia. Med J Aust. 2014;201(5):295-7.
  33. Carter SM. Cancer Prevention Services, Utilization of. In: Cockerham WC, Dingwall R, Quah SR, editors. The Wiley Blackwell Encyclopedia of Health, Illness, Behavior, and Society: John Wiley & Sons, Ltd; 2014. p. 190–2.
  34. Rychetnik L, Carter SM, Barratt A, Irwig L. Expanding the evidence on cancer screening: the value of scientific, social and ethical perspectives. The Medical journal of Australia. 2013;198(10):536-9.
  35. Rychetnik L, Carter SM, Abelson J, Thornton H, Barratt A, Entwistle VA, et al. Enhancing Citizen Engagement in Cancer Screening Through Deliberative Democracy. J Natl Cancer Inst. 2013;105(6):380-6.
  36. Thesis: Jane Hannah Williams. An empirical ethics analysis of cervical screening organisation 15-Jun-2016
  37. Thesis: Lisa Michelle Parker. An empirical ethics analysis of breast cancer screening in Australia.  7-Mar-2016
  38. Thesis: Kristen Pickles. Prostate cancer screening in primary care: Doctors’ perspectives on prostate-specific antigen (PSA) testing of asymptomatic men in Australia and the United Kingdom.

One thought on “Publications

  1. Pingback: The Cancer Screening Ethics study | Cancer Screening Ethics

Comments are closed.